Predictors of ovarian failure after chemotherapy in young breast cancer patients

年轻乳腺癌患者化疗后卵巢衰竭的预测因素

基本信息

  • 批准号:
    7945364
  • 负责人:
  • 金额:
    $ 10.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This mentored research award will prepare the candidate to become an independent investigator in reproductive epidemiology. Specifically, this proposal will enable the principal investigator to: 1) conduct a prospective cohort study; 2) learn methods in genetics epidemiology and predictive modeling; 3) collaborate with researchers in multiple disciplines; and 4) gather data for an R01 submission. More than two million American women are breast cancer survivors. The large number of reproductive aged women with breast cancer provides a unique opportunity to study the impact of this devastating disease and treatment on ovarian aging and reproduction. Accurately characterizing and predicting ovarian function in young breast cancer patients is an important issue to survivors because of implications on reproductive issues such as fertility and menopause and cancer survival. Current predictors of ovarian failure after chemotherapy are limited to age and chemotherapy regimen. The goal of this proposal is to identify significant hormonal, genetic and ovarian morphometric markers associated with ovarian failure after adjuvant chemotherapy. A 5-year prospective cohort study of pre-menopausal breast cancer patients, followed from diagnosis to post-chemotherapy, is proposed. We will test the hypotheses that: 1). Breast cancer patients with lower pre-chemotherapy anti-Mullerian hormone and inhibin B levels and higher pre-chemotherapy FSH levels will be more likely to develop ovarian failure after adjuvant chemotherapy; 2). Breast cancer patients with drug metabolizing enzyme polymorphisms resulting in higher cyclophosphamide exposure are more likely to develop ovarian failure after cyclophosphamide-based adjuvant chemotherapy; 3). Breast cancer patients with smaller pre-chemotherapy ovarian volume, diameter and antral follicle count, and larger changes in these measurements pre- and post-chemotherapy are more likely to develop ovarian failure; 4). A predictive index using variables from these aims can be derived to identify patients at high risk for ovarian failure after therapy. PUBLIC HEALTH RELEVANCE: This study will identify hormonal, genetic and ovarian imaging markers to predict ovarian failure after chemotherapy. These tools will assist young breast cancer patients and their physicians in making treatment decisions that would impact cancer survival and reproduction.
描述(由申请人提供):这个指导研究奖将准备候选人成为生殖流行病学的独立调查员。具体而言,该提案将使主要研究者能够:1)进行前瞻性队列研究; 2)学习遗传学流行病学和预测建模方法; 3)与多个学科的研究人员合作; 4)收集R 01提交的数据。 超过200万美国女性是乳腺癌幸存者。大量的育龄妇女乳腺癌提供了一个独特的机会,研究这种毁灭性的疾病和治疗对卵巢衰老和生殖的影响。准确地描述和预测年轻乳腺癌患者的卵巢功能对幸存者来说是一个重要的问题,因为这会影响生育、绝经和癌症生存等生殖问题。目前化疗后卵巢功能衰竭的预测因素仅限于年龄和化疗方案。 本研究的目的是确定与辅助化疗后卵巢功能衰竭相关的重要激素、遗传和卵巢形态学标志物。一项为期5年的前瞻性队列研究,绝经前乳腺癌患者,从诊断到化疗后,建议。我们将检验以下假设:1)。化疗前抗苗勒管激素和FSH B水平较低、化疗前FSH水平较高的乳腺癌患者,辅助化疗后发生卵巢功能衰竭的可能性较大; 2).具有药物代谢酶多态性导致环磷酰胺暴露量较高的乳腺癌患者更容易在基于环磷酰胺的辅助化疗后发生卵巢功能衰竭; 3)。乳腺癌患者化疗前卵巢体积、直径和窦卵泡计数较小,化疗前后这些测量值变化较大,更容易发生卵巢功能衰竭; 4)。使用这些目标的变量的预测指数可以用来识别治疗后卵巢功能衰竭的高风险患者。 公共卫生相关性:这项研究将确定激素,遗传和卵巢成像标志物,以预测化疗后卵巢衰竭。这些工具将帮助年轻的乳腺癌患者及其医生做出影响癌症生存和繁殖的治疗决定。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hui-Chun Irene Su其他文献

Hui-Chun Irene Su的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hui-Chun Irene Su', 18)}}的其他基金

Pilot Project 1: Creating Bridges to Reproductive Health Care for Rural Adolescent and Young Adult Cancer Survivors
试点项目 1:为农村青少年和青年癌症幸存者搭建生殖保健桥梁
  • 批准号:
    10762275
  • 财政年份:
    2023
  • 资助金额:
    $ 10.5万
  • 项目类别:
Evaluation of a telehealth oncofertility care intervention in adolescent and young adult cancer patients: a stepped wedge cluster randomized controlled trial
对青少年和年轻成年癌症患者的远程医疗肿瘤生育护理干预的评估:阶梯式楔形集群随机对照试验
  • 批准号:
    10587766
  • 财政年份:
    2022
  • 资助金额:
    $ 10.5万
  • 项目类别:
The Reproductive Window in Young Adult Cancer Survivors
年轻癌症幸存者的生殖窗口
  • 批准号:
    9067825
  • 财政年份:
    2014
  • 资助金额:
    $ 10.5万
  • 项目类别:
The Reproductive Window in Young Adult Cancer Survivors
年轻癌症幸存者的生殖窗口
  • 批准号:
    8926238
  • 财政年份:
    2014
  • 资助金额:
    $ 10.5万
  • 项目类别:
The Reproductive Window in Young Adult Cancer Survivors
年轻癌症幸存者的生殖窗口
  • 批准号:
    8751598
  • 财政年份:
    2014
  • 资助金额:
    $ 10.5万
  • 项目类别:
Predictors of ovarian failure after chemotherapy in young breast cancer patients
年轻乳腺癌患者化疗后卵巢衰竭的预测因素
  • 批准号:
    8013386
  • 财政年份:
    2009
  • 资助金额:
    $ 10.5万
  • 项目类别:
Predictors of ovarian failure after chemotherapy in young breast cancer patients
年轻乳腺癌患者化疗后卵巢衰竭的预测因素
  • 批准号:
    8514411
  • 财政年份:
    2009
  • 资助金额:
    $ 10.5万
  • 项目类别:
Predictors of ovarian failure after chemotherapy in young breast cancer patients
年轻乳腺癌患者化疗后卵巢衰竭的预测因素
  • 批准号:
    8324495
  • 财政年份:
    2009
  • 资助金额:
    $ 10.5万
  • 项目类别:
Predictors of ovarian failure after chemotherapy in young breast cancer patients
年轻乳腺癌患者化疗后卵巢衰竭的预测因素
  • 批准号:
    8104288
  • 财政年份:
    2009
  • 资助金额:
    $ 10.5万
  • 项目类别:

相似海外基金

3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
  • 批准号:
    10556192
  • 财政年份:
    2023
  • 资助金额:
    $ 10.5万
  • 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
  • 批准号:
    10315227
  • 财政年份:
    2021
  • 资助金额:
    $ 10.5万
  • 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
  • 批准号:
    443988
  • 财政年份:
    2021
  • 资助金额:
    $ 10.5万
  • 项目类别:
    Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
  • 批准号:
    20K09011
  • 财政年份:
    2020
  • 资助金额:
    $ 10.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
  • 批准号:
    19K09130
  • 财政年份:
    2019
  • 资助金额:
    $ 10.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
  • 批准号:
    19K18225
  • 财政年份:
    2019
  • 资助金额:
    $ 10.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
  • 批准号:
    18K16337
  • 财政年份:
    2018
  • 资助金额:
    $ 10.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
  • 批准号:
    10005254
  • 财政年份:
    2018
  • 资助金额:
    $ 10.5万
  • 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
  • 批准号:
    9763320
  • 财政年份:
    2018
  • 资助金额:
    $ 10.5万
  • 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
  • 批准号:
    18K07341
  • 财政年份:
    2018
  • 资助金额:
    $ 10.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了